Roche: Japan approves Rozlytrek

(CercleFinance.com) - Roche reports that the Japanese Ministry of Health has approved its Rozlytrek (entrectinib) for adult and paediatric patients with NTRK fusion-positive advanced recurrent solid tumours.


This approval in Japan is based on positive data from the pivotal phase II STARTRK-2 study showing a reduction of more than half of the tumor in ten different types of tumors.

The laboratory points out that the NTRK fusion gene has been identified in many types of difficult-to-treat tumors, including pancreatic, thyroid, salivary gland, breast, colorectal and lung tumors.


Copyright (c) 2019 CercleFinance.com. All rights reserved.